Histologic Subtype and Immunophenotype: Description of the Patients, Outcome, Prognostic Value of Histologic Typing, and Immunophenotyping
| Characteristics . | MD . | Patients . | Outcome . | Univariate Analysis P* . | Multivariate Analysis P† . | ||
|---|---|---|---|---|---|---|---|
| No. of Patients . | % . | No. of Events . | 3-yr EFS . | ||||
| All | 82 | 25 | 66% [54-76%] | ||||
| Histologic subtype | 8 | .02‡ | .35‡ | ||||
| Common type | 48 | 65% | 12 | 73% [58-85%] | |||
| Lympho-histiocytic (LH) | 13 | 17% | 8 | 16% [3-53%] | |||
| Pure LH | 7 | 9% | |||||
| Common plus LH | 6 | 8% | |||||
| Other | 13 | 17% | 3 | 76% [48-91%] | |||
| Small-cell variant | 5 | 7% | |||||
| Common plus small cell | 6 | 8% | |||||
| Giant-cell variant | 1 | 1% | |||||
| Mixed (other) | 1 | 1% | |||||
| Immunophenotype | |||||||
| T/null/B phenotype | 12 | .11 | .27 | ||||
| T | 61 | 87% | 16 | 70% [56-81%] | |||
| Null | 9 | 13% | 5 | 44% [19-73%] | |||
| B | 0 | 0% | — | ||||
| CD30 | 0 | 82 | 100% | ||||
| EMA | 0 | 82 | 100% | ||||
| ALK-1 | 2 | 74 | 93% | 24 | 64% [52-75%] | .32 | — |
| BNH9 | 4 | 61 | 78% | 19 | 66% [52-77%] | .66 | — |
| Characteristics . | MD . | Patients . | Outcome . | Univariate Analysis P* . | Multivariate Analysis P† . | ||
|---|---|---|---|---|---|---|---|
| No. of Patients . | % . | No. of Events . | 3-yr EFS . | ||||
| All | 82 | 25 | 66% [54-76%] | ||||
| Histologic subtype | 8 | .02‡ | .35‡ | ||||
| Common type | 48 | 65% | 12 | 73% [58-85%] | |||
| Lympho-histiocytic (LH) | 13 | 17% | 8 | 16% [3-53%] | |||
| Pure LH | 7 | 9% | |||||
| Common plus LH | 6 | 8% | |||||
| Other | 13 | 17% | 3 | 76% [48-91%] | |||
| Small-cell variant | 5 | 7% | |||||
| Common plus small cell | 6 | 8% | |||||
| Giant-cell variant | 1 | 1% | |||||
| Mixed (other) | 1 | 1% | |||||
| Immunophenotype | |||||||
| T/null/B phenotype | 12 | .11 | .27 | ||||
| T | 61 | 87% | 16 | 70% [56-81%] | |||
| Null | 9 | 13% | 5 | 44% [19-73%] | |||
| B | 0 | 0% | — | ||||
| CD30 | 0 | 82 | 100% | ||||
| EMA | 0 | 82 | 100% | ||||
| ALK-1 | 2 | 74 | 93% | 24 | 64% [52-75%] | .32 | — |
| BNH9 | 4 | 61 | 78% | 19 | 66% [52-77%] | .66 | — |
Under patients, the number of patients in the subsets is given. Under outcome, the number of events in the subsets is given. For the variables defining two subgroups, only the data concerning the group with the poorer outcome have been given. The number of events in the complementary group can be deducted by subtraction.
Abbreviation: MD, number of missing data for the variable.
P value of the two-tailed logrank test comparing each subset with the complementary group, adjusted on the chemotherapy protocol (univariate analysis).
P value in the multivariate analysis, adjusted on the chemotherapy regimen.
Because EFS of the common type overlaps with that of the so-called others, these two groups have been pooled, to conduct a comparison between lympho-histiocytic (pure or mixed) and non–lympho-histiocytic (P = .02). This binary variable has been tested in the Cox model.